Tirzepatide vs GLP-1 RA in Type 2 Diabetes
JAMA Network Open
Summary
This study analyzed the association of tirzepatide with all-cause mortality and adverse cardiovascular and kidney outcomes compared with GLP-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes. Results indicated significantly lower hazards of all-cause mortality, major adverse cardiovascular events (MACEs), kidney events, acute kidney injury, and major adverse kidney events for patients treated with tirzepatide compared to GLP-1 RA treatment. The retrospective cohort study utilized data from the US Collaborative Network of TriNetX, involving 140,308 patients. Findings suggest tirzepatide provides superior clinical benefits for cardiovascular and kidney health in type 2 diabetes management compared with GLP-1 RAs, supporting its integration into therapeutic strategies for this patient population.
Study Design
Interventions
Study Type
Outcomes
Duration and Size
Study Population
Age Range
Sex
Geography
Other Criteria
Methodology
A retrospective cohort study leveraging TriNetX database with propensity score matching and Cox proportional hazards regression for outcome analysis.
Interventions
Interventions included tirzepatide administration and comparison with GLP-1 receptor agonists, assessing mortality, cardiovascular, and kidney outcomes.
Key Findings
Tirzepatide treatment was associated with significantly lower risks of mortality and major cardiovascular and kidney events compared with GLP-1 RAs.
Comparison with other Studies
Compared with previous studies, tirzepatide shows superior outcomes in glycemic control, weight loss, and cardiovascular protection, aligning with SURPASS trials but providing novel direct comparison with GLP-1 RAs.
Journal Reference
Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Netw Open. 2024;7(8):e2427258. doi:10.1001/jamanetworkopen.2024.27258
Related and Discussions
A drug approved to treat Type 2 diabetes is extremely effective at reducing obesity, according to a new study.
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control and weight loss in type 2 diabetes: a systematic review and network meta-analysis
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Patients With Type 2 Diabetes: A Retrospective Cohort Study
Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
In this cohort study of patients with type 2 diabetes mellitus, treatment with tirzepatide was associated with lower hazards of all-cause mortality and major adverse cardiovascular events.
Nuevo estudio compara semaglutida y tirzepatida en 18.386 adultos con sobrepeso/obesidad: Primer estudio de efectividad comparada en el mundo real.
A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists.
Tirzepatide para el control del sobrepeso y la obesidad marca una nueva era en el tratamiento, permitiendo a muchos lograr una pérdida de peso ≥ 20%.
An observational study found adults with type 2 diabetes have lower risks for death and major adverse cardiovascular and kidney events if they use tirzepatide compared with GLP-1 receptor agonists.
Tirzepatide: A New Frontier for Diabetes Management
Stay informed. Stay ahead.
Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.